

Lev Sverdlov, M.D. Ph.D. Consulting Profile

Professional Profile and Education	
<ul style="list-style-type: none">• Job Profiles: Physician, epidemiologist, clinical and outcomes research scientist, health care predictive analytics• Background: Clinical, Research, Management• Experience: Health care, Pharmaceutical companies, Academic, Government, and Consulting organizations.	<ul style="list-style-type: none">• Doctor of Medical Sciences (Dr. Hab.), Bekhterev Psychoneurological Research Institute• Ph.D., Bekhterev Psychoneurological Research Institute• M.D., Saint Petersburg State Pediatric Medical Academy

Quotes from Colleagues and Clients:

“Dr. Sverdlov has a terrific desire for the big picture (e.g., managed care)... He orchestrated the activities of three physician members and numerous other health care professionals, and designed and initialed a substantial, unique and innovative cost-cutting prevention/disease management program for cardiovascular and cerebrovascular disorders” “Aside from being an Epidemiologist, and for contributing original solutions for “dead end” problems on injury prevention issues affecting military readiness, Dr. Sverdlov was a military health care database wizard.”

John P. Mitchell, LtCol, USAF, MC (M.D., FACP, FCCP, CPE)
Director, Population Health Office, David Grant Medical Center
Fmr. Chief Consultant to Air Force Surgeon General for Disease Management Programs
Fmr. Commander, US Defense Medical Readiness Training Institute)

“Dr. Sverdlov devoted himself to identifying population trends. It was his effort that catapulted David Grant Medical Center into a progressive Population Based Health Care Program.” “His ability to see beyond the obvious and his devotion to quality health care based upon the most current research makes him a most valuable resource.”

Janet V Phelps, LtCol, USAF, NC
Chief Health Care Integrator

Contact Information	
Redmond Analytics Windsor Building Ste. 109 401 100 th Ave NE Bellevue, WA 98004	Direct: 425-633-2216 Cell: 862-206-9283 e-mail: lev@RedmondAnalytics.com

Program Design, Implementation and Evaluation

- Managed care.
- Disease prevention and management.
- Program design, development and evaluation.

Database Experience

- | | |
|---|---|
| <ul style="list-style-type: none">• Database content design and development.• Analytic Team Leader for the development of the National Treatment Outcome Monitoring System (NTOMS).• Scientific Program Manager for a launch phase of the development of a high-tech platform (MS Amalga) for a statewide data collection system for outcomes research. | <p>Hands-on research experience includes:</p> <ul style="list-style-type: none">• US SAMHSA databases (TEDS, N-SSATS, and ADSS)• Population claims databases (Ingenix, Medicaid, Blue Cross and Blue Shield)• UK and US electronic medical record databases (NHS, MediPlus, GPRD)• Military health care databases (CHCS, ADS, Quantum, Trendpath, Trendstar) |
|---|---|

Outcomes Research and Health Economics

- | | |
|---|---|
| <ul style="list-style-type: none">• Comparative effectiveness research.• Predictive modeling.• Drug and services utilization.• Populations at risk.• Populations with potentially high ROI.• Provider performance measurement. | <ul style="list-style-type: none">• Developed a financial risk predictive model with substantially better performance (<i>PPV</i>, R^2, etc.) than models then on the market; used by UK NHS for predicting ER visits, re-hospitalization, other resource/service utilization.• Led study of factors affecting retention in substance abuse treatment. Due to glowing review from SAMHSA Office of Policy Development and Planning, commissioned to develop a business oriented version of study for SAMHSA Administrator and Senior Staff. |
|---|---|

Epidemiology

- | | |
|---|---|
| <ul style="list-style-type: none">• Prevalence, incidence and natural course of chronic disorders.• Age-related disorders.• Short-term and long-term effects of prolonged medication in age-related disorders.• Substance abuse. | <ul style="list-style-type: none">• Led study having discovered and identified relapse high risk periods in schizophrenia and affective psychoses• Described a possible bias in longitudinal studies on treatment of age-related disorders |
|---|---|

Drug Safety and Clinical Risk Management

- | | |
|--|---|
| <ul style="list-style-type: none">• Multiple therapeutic areas and medicines in all stages of development.• Detailed knowledge of EU and US regulations. Periodic and <i>ad hoc</i> safety reports.• Signal evaluation analyzing adverse effects, claims and medical record databases. | <ul style="list-style-type: none">• Member of <i>Risk Management Working Group</i>, Schering-Plough Corporation, developing and implementing the <i>Corporate Global Risk Management Process</i>.• Performed key study at SPRI investigating the alleged association between Statins and ALS, later confirmed by a study conducted by FDA. |
|--|---|